Sartorius Stedim Biotech S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SDMHF research report →
Price Chart
About the company
Sartorius Stedim Biotech S. A. , a global entity and a subsidiary of Sartorius AG, delivers critical instruments, consumables, and services tailored for the biopharmaceutical industry.
- CEO
- Rene Faber
- IPO
- 2009
- Employees
- 10,265
- HQ
- Aubagne, PAC, FR
Get TickerSpark's AI analysis on SDMHF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $24.03B
- P/E
- 66.05
- Fwd P/E
- 50.68
- PEG
- 2.79
- P/S
- 7.01
- P/B
- 4.90
- EV/EBITDA
- 26.20
- Div Yield
- 0.31%
- Gross Margin
- 44.55%
- Op Margin
- 19.36%
- Net Margin
- 10.58%
- ROE
- 7.71%
- ROIC
- 5.95%
Latest fiscal year · YoY change
- Revenue
- $2.97B+6.7%
- Gross Profit
- $1.34B+11.4%
- Op Income
- $548.79M
- Net Income
- $265.50M+51.6%
- EPS
- $2.73+50.8%
- OCF Growth
- -33.9%
- FCF Growth
- -69.4%
- 52W High
- $264.30
- 52W Low
- $178.30
- 50D MA
- $241.28
- 200D MA
- $212.61
- Beta
- 1.15
- RSI (14)
- 55
- Avg Volume
- 1.78K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Sartorius said 9M 2026 growth and profitability improved, with LPS outperforming, Bioprocessing recovering steadily, and full-year guidance confirmed with a higher LPS outlook.· October 22, 2026
- 9M group sales grew 6.9% in constant currencies reported, or 8.1% on an operational basis excluding tariff compensation; underlying EBITDA rose 6.9% to EUR 828 million and margin expanded to 30.2%.
- Bioprocessing remained on a recovery path: operational sales grew 8.1% constant currency, driven by consumables and a year-on-year improvement in nonrecurring equipment sales.
- Lab Products & Services beat expectations, with operational sales up 8.3% constant currency and management citing bioanalytics strength, AI-related workflows, and some Q3 pull-forward.
- Cash generation was strong: free cash flow rose 55% to EUR 310 million, net debt fell to EUR 3.68 billion, and leverage improved to 3.3x.
- Management confirmed full-year group and BPS guidance and raised LPS outlook and margin expectations after the strong 9-month performance.
For the first 9 months of 2026, group operational sales grew 8.1% in constant currencies excluding tariff compensation, or 6.9% including it. Underlying EBITDA increased 6.9% to EUR 828 million, with the margin at 30.2% (+50 bps year over year). Underlying net profit rose around 7% to EUR 260 million, and underlying EPS increased to EUR 3.76 per ordinary share and EUR 3.77 per preference share. Reported net profit attributable to shareholders increased 51% to EUR 188 million. Operating cash flow was EUR 562 million, up about 10%, and free cash flow increased 55% to EUR 310 million. Full-year guidance was confirmed for the group and Bioprocessing: management expects operational group sales growth around the midpoint of the 5% to 9% range and an underlying EBITDA margin slightly above 30%; BPS guidance was unchanged, with margin expected slightly above 32%. For LPS, management raised growth expectations to around the upper end of the 2% to 6% range and margin guidance to slightly above 21%. CapEx ratio guidance was lowered modestly to around 12% from around 12.5%, and year-end net debt to EBITDA remains expected at slightly above 3x.
Michael Grosse framed the quarter as a solid execution update, emphasizing that both divisions contributed to growth, profitability improved, and cash flow remained strong. He highlighted a recovery in equipment/nonrecurring demand, strength in consumables, and progress in AI-enabled workflows and process intensification. His tone was constructive and confident, while also stressing that Q3 strength should not simply be extrapolated into Q4 because of timing effects, tough comps, tariff headwinds, and MATTEK being in the baseline.
Florian Funck focused on the mechanics behind the numbers: group operational sales growth of 8.1% excluding customer tariff compensation versus 6.9% including it, with tariff refunds of EUR 31 million received in 9M out of roughly EUR 40 million claimed. He pointed to underlying EBITDA of EUR 828 million and margin expansion to 30.2%, supported by higher volumes and operating leverage, and noted free cash flow of EUR 310 million helped by lower CapEx. On the balance sheet, he cited net debt of EUR 3.68 billion, leverage of 3.3x, and an equity ratio of 42.8%, and said the company remains on a disciplined deleveraging path while still investing.
Analysts pressed management on the durability of bioprocessing demand, the meaning of Q3 strength in LPS, the risk from a competitor’s 5,000-liter single-use bioreactor, and the timing/scale of U.S. reshoring-related orders. Management repeatedly said the demand picture is improving steadily but is not yet a new run rate, that LPS strength was driven mainly by recurring revenue and broader underlying demand rather than a single tender event, and that the company believes most customer needs are covered by 2,000-liter-and-below systems. On reshoring, management said order opportunities for late 2027 and 2028 still look intact, but they are not yet treating it as fully structural.
The call showed broad-based momentum: consumables remain healthy, equipment recovery is continuing, and LPS is gaining traction in bioanalytics and AI-enabled drug discovery. Management also pointed to stronger visibility, stronger cash generation, and a better balance sheet, while raising LPS guidance and margin expectations. The reorganization and reporting changes were presented as strategic simplifications that could improve customer experience and operational efficiency.
Management flagged several near-term caveats: Q3 benefited from pull-forward and timing effects in LPS, tariff surcharges are now a headwind rather than a tailwind, and Q4 faces a tough comparison base. They also said advanced therapies orders remain volatile, the timing of the remaining tariff refunds is uncertain, and they are not yet treating equipment or reshoring-driven demand as fully structural. In addition, management would not quantify how much of LPS’s strength came from pull-forward versus underlying demand.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 28.5%
- Shares Outstanding
- 97.30M
- Float Shares
- 27.70M
Held by 14 ETFs
Biggest fund positions in SDMHF by dollar value.
Our SDMHF coverage
Recent articles, reports, and earnings notes.
No research on SDMHF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SDMHF report →Baron International Growth Fund Q2 2026 Portfolio Activity
seekingalpha.com · Sep 15
Sartorius Stedim Biotech S.A. (SRTOY) Q4 2025 Earnings Call Transcript
seekingalpha.com · Feb 3
Sartorius Stedim Biotech and Nanotein Technologies Partner to Advance Cell Therapy Manufacturing
businesswire.com · Aug 11
Bio Usawa Biotechnology and Sartorius Stedim Biotech Forge Partnership to Pioneer Biopharmaceutical Manufacturing in Africa
globenewswire.com · Jul 29
Sartorius Stedim Biotech and Sensible Biotechnologies Partner to Scale Up Sensible's Unique Cell-Based mRNA Design and Manufacturing Platform
businesswire.com · Jul 9
Sartorius, Sartorius Stedim Biotech shares jump after results beat
reuters.com · Jan 28
Sartorius Stedim Biotech S.A. (SDMHF) Q3 2024 Earnings Call Transcript
seekingalpha.com · Oct 18
Sartorius Stedim Biotech S.A. (SDMHF) H1 2024 Earnings Call Transcript
seekingalpha.com · Jul 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.